Novel Pyrimidine Scaffolds as Anti-Tubercular Agents Targeting Enoyl Acyl Carrier Protein Reductase: A Molecular Docking Study

In recent years, tuberculosis (TB) has continued to be a global public health concern.The screening of novel bioactive compounds with novel targets and distinct mechanisms of action is desperately needed.Pyrimidine-cored heterocyclic molecules have become increasingly significant in medical chemistry.The 3,4 dihydropyrimidine scaffold is crucial to the development of anti-tuberculosis drugs since its derivatives have demonstrated exceptional efficacy.We created a new series of 3,4 dihydropyrimidine derivatives in this article and used Autodock Vina to perform docking studies on them.Isoniazid was the standard drug used, and all drugs had good binding affinities with the enoyl acyl carrier protein reductase.